Page Not Found
You asked for http://www.clinuvel.com/en/skin-conditions/skin-cancer/actinic-keratosis, but despite our computers looking very hard, we could not find it. What happened ?
- the link you clicked to arrive here has a typo in it
- or somehow we removed that page, or gave it another name
- or, quite unlikely for sure, maybe you typed it yourself and there was a little mistake ?
It's not the end of everything though : you may be interested in the following pages on our site:
Clinuvel Blog Posts
In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...Read More
The biennial Porphyrins & Porphyrias conference is the only international meeting of global key opinion leaders on the group of...Read More
Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...Read More
The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) an...Read more